Cargando…

Cancer immunotherapy strategies that target the cGAS-STING pathway

Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhuoying, Zeng, Yue, Peng, Yurong, Liu, Junqi, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639746/
https://www.ncbi.nlm.nih.gov/pubmed/36353640
http://dx.doi.org/10.3389/fimmu.2022.996663
_version_ 1784825705323823104
author Tian, Zhuoying
Zeng, Yue
Peng, Yurong
Liu, Junqi
Wu, Fang
author_facet Tian, Zhuoying
Zeng, Yue
Peng, Yurong
Liu, Junqi
Wu, Fang
author_sort Tian, Zhuoying
collection PubMed
description Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges.
format Online
Article
Text
id pubmed-9639746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96397462022-11-08 Cancer immunotherapy strategies that target the cGAS-STING pathway Tian, Zhuoying Zeng, Yue Peng, Yurong Liu, Junqi Wu, Fang Front Immunol Immunology Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9639746/ /pubmed/36353640 http://dx.doi.org/10.3389/fimmu.2022.996663 Text en Copyright © 2022 Tian, Zeng, Peng, Liu and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tian, Zhuoying
Zeng, Yue
Peng, Yurong
Liu, Junqi
Wu, Fang
Cancer immunotherapy strategies that target the cGAS-STING pathway
title Cancer immunotherapy strategies that target the cGAS-STING pathway
title_full Cancer immunotherapy strategies that target the cGAS-STING pathway
title_fullStr Cancer immunotherapy strategies that target the cGAS-STING pathway
title_full_unstemmed Cancer immunotherapy strategies that target the cGAS-STING pathway
title_short Cancer immunotherapy strategies that target the cGAS-STING pathway
title_sort cancer immunotherapy strategies that target the cgas-sting pathway
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639746/
https://www.ncbi.nlm.nih.gov/pubmed/36353640
http://dx.doi.org/10.3389/fimmu.2022.996663
work_keys_str_mv AT tianzhuoying cancerimmunotherapystrategiesthattargetthecgasstingpathway
AT zengyue cancerimmunotherapystrategiesthattargetthecgasstingpathway
AT pengyurong cancerimmunotherapystrategiesthattargetthecgasstingpathway
AT liujunqi cancerimmunotherapystrategiesthattargetthecgasstingpathway
AT wufang cancerimmunotherapystrategiesthattargetthecgasstingpathway